Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657159 | 0.87 | BRD4 (0.34) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23356619 | 0.86 | ACP3 (0.40) | ACP3MEN1KMT2A | |
| SCHEMBL29657157 | 0.76 | BRD4 (0.35) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23356610 | 0.72 | BRD4 (0.35) | ACP3MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29657202 | 0.65 | BRD4 (0.44) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23356571 | 0.63 | LMNA (0.34) | CYP1A2CYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL29657243 | 0.61 | ALDH1A1 (0.43) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28697375 | 0.59 | ACP3 (0.43) | ACP3NPSR1MEN1KMT2AGAA | |
| SCHEMBL29657149 | 0.58 | BRD4 (0.34) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28263462 | 0.57 | ALDH1A1 (0.39) | MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | claimed |
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | CBR1, POR, CAT | ACP3 3234/4885NPSR1 2341/4885MEN1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.